Introduction: Malignant pleural mesothelioma (MPM) is a highly aggressive malignancy in which the mitogenactivated protein kinase pathway plays a critical role in the regulation of tumorigenesis. Hyaluronic acid (HA) is a major component of the extracellular matrix, and elevated HA levels with a concurrent increase in malignant properties are associated with MPM.
Methods:
We evaluated the effects of trametinib, a mitogen-activated protein kinase (MEK) inhibitor, and 4-methylumbelliferone (4-MU), an HA synthesis inhibitor, alone and in combination on MPM cells in vitro and in vivo. We studied the effects of trametinib, 4-MU, and their combination on MPM cells by using cell viability assays, Western blot analysis, and a mouse xenograft model.
Results: Trametinib and 4-MU exhibited antiproliferative activity in MPM cells. Trametinib blocked MEK-dependent extracellular signal-regulated kinase (ERK) phosphorylation and decreased CD44 expression in a concentrationdependent manner. Trametinib inhibited the expression of Fra-1 (the activator protein 1 [AP1] component), inhibited ERK phosphorylation, and decreased CD44 expression. 4-MU inhibited ERK phosphorylation but not CD44 expression.
In a mouse xenograft model, trametinib and 4-MU alone suppressed tumor growth compared with a control. The combination had a greater inhibitory effect than either monotherapy. Immunohistochemical analysis showed that trametinib treatment alone significantly reduced expression of programmed cell death 1 ligand 1. Furthermore, the combination of trametinib and 4-MU resulted in higher expression of programmed cell death 1 and programmed cell death 1 ligand 1 than did the 4-MU treatment alone.
Introduction
Malignant pleural mesothelioma (MPM), an uncommon but aggressive malignancy of the pleura associated with exposure to asbestos, has an extremely poor prognosis. The median survival time after diagnosis for MPM is 9 to 12 months. The worldwide incidence of MPM is *Corresponding author.
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predicted to increase in the upcoming decades. [1] [2] [3] MPM is relatively resistant to currently available multimodality therapy, which consists of surgery, cytotoxic chemotherapy, and radiation. 4 Although pemetrexed, a multitargeted antifolate, has been approved in combination with cisplatin as the first-line agent for the treatment of MPM, there have been few other advances. 5 Therefore, novel effective therapeutic strategies are urgently needed to improve patient outcomes.
The mitogen-activated protein kinase (MAPK) pathway plays critical roles in the regulation of cell proliferation, growth, differentiation, and survival. Dysregulation of the MAPK pathway contributes to the formation of a variety of tumors, including MPM. A component of the MAPK pathway, mitogen-activated protein kinase (MEK), has been identified as a promising target for novel therapeutic strategies. 6, 7 Several MEK inhibitors have been developed, and some of them have shown efficacy in clinical trials. 8 Trametinib, a potent and selective allosteric inhibitor of MEK1/2, has been shown to provide a survival benefit over cytotoxic chemotherapy in patients with V600 BRAFmutant metastatic melanoma. 9 Trametinib is administered orally and has a longer circulating half-life than previously evaluated MEK inhibitors. In addition, it inhibits not only MEK-dependent extracellular signal-regulated kinase (ERK) phosphorylation but also MEK1/2 activation by preventing Raf phosphorylation of MEK. 10 Hyaluronic acid (HA) is a linear high-molecular-weight glycosaminoglycan composed of repeating disaccharide units of N-acetyl-glucosamine and glucuronic acid. HA is synthesized by HA synthase 1 (HAS1), HAS2, and HAS3. Synthesized HA molecules bind to cell surface receptors such as CD44, CD168/hyaluronan mediated motility receptor, lymphatic vessel endothelial hyaluronan receptor 1, hyaluronic acid receptor for endocytosis/ stabilin-2, and Toll-like receptor 2 and Toll-like receptor 4, 11, 12 and interaction of HA with these receptors modulates the intracellular signaling pathways, cell proliferation, motility, and invasive properties of malignant cells. 12, 13 The HA level is elevated in most human malignancies, and it is associated with poor prognosis. In MPM, HA is produced not only by mesothelioma cells but also by the surrounding normal mesothelial cells and fibroblasts.
14,15 Elevated HA levels are associated with an increase in the malignant properties of MPM cells. 16 The cell surface receptor CD44 is expressed in MPM cells but not in normal mesothelial cells. 17, 18 4-methylumbelliferone (4-MU) inhibits HA synthesis by depletion of cellular uridine diphosphate-glucuronic acid and downregulation of HAS2 and HAS3. 19 4-MU has been used as an oral choleretic and antispasmodic drug for many years, and its safety in humans has previously been established. Recently, several studies have demonstrated that 4-MU inhibits cell proliferation in several tumor types, including melanoma, 20 osteosarcoma, 21 esophageal squamous cell carcinoma, 22 breast cancer, 23 prostate cancer, 24 hepatocellular carcinoma, 25, 26 and leukemia. 27 However, its mechanism of action is not well understood.
Programmed cell death 1 (PD-1) is an immunomodulatory molecule that negatively regulates T-cell immune responses. Programmed cell death 1 ligand 1 (PD-L1) is one of the two ligands for PD-1; it is an inducible ligand expressed by a variety of tissues, including solid tumors. Immune checkpoint inhibitors targeting PD-1 and PD-L1 have antitumor activity in solid tumors. Inhibition of MAPKs including BRAF and MEK modulates immune cell function in the tumor and tumor microenvironment. 28, 29 In this study, we examined whether trametinib and/ or 4-MU exhibited antitumor effects and affected PD-1 and PD-L1, which are immune checkpoint molecules, on MPM cells.
Materials and Methods

Cell Cultures
The MPM cell lines NCI-H226, NCI-H2452, NCI-H2052, and MSTO-211H were obtained from the American Type Culture Collection (Manassas, VA). The cell lines were characterized by the the American Type Culture Collection using their standard testing procedures, which include tests for postfreeze viability, growth properties, morphologic features, mycoplasma contamination, postfreeze cell growth, species determination with isoenzyme and short tandem repeat analysis, and a sterility test. The cells were expanded and stored according to the supplier's instructions. All cells were passaged in our laboratory for fewer than 6 months after receipt. The cells were cultured in Roswell Park Memorial Institute-1640 medium (Sigma-Aldrich, St. Louis, MO) supplemented with 10% fetal bovine serum (Nichirei Biosciences, Tokyo, Japan) at 37 C in a humidified incubator with 5% CO 2 in air.
Reagents
Trametinib was purchased from LC Laboratories (Woburn, MA). 4-MU was purchased from Sigma-Aldrich. Stock solutions of trametinib and 4-MU were prepared in DMSO (Wako Pure Chemical Industries, Osaka, Japan 
Cell Viability Assay
MPM cells (5 Â 10 3 cells per well) were plated in 96-well plates and incubated at 37 C in 5% CO 2 for 24 hours. The cells were treated with various concentrations of trametinib (0-100 mM) and 4-MU (0-1 mM) for 72 hours. Cell viability was determined with a WST-8 assay (Cell Counting Kit-8, Dojindo Molecular Technologies, Rockville, MD) according to the manufacturer's protocol. The absorbance was measured using a SpectraMax Plus 384 device (Molecular Devices, Sunnyvale, CA) at a wavelength of 450 nm.
Flow Cytometry
NCI-H226 or MSTO-211H cells were treated with trametinib (10 nM, 1 mM) or 4-MU (100 mM, 1 mM) for 90 minutes. Cells were collected and stained with propidium iodide (PI) and fluorescein isothiocyanatelabeled annexin V using the Annexin V-FITC/PI Kit System for Detection of Apoptosis (Beckman Coulter, Fullerton, CA) according to the manufacturer's instructions. Cells were analyzed using a BD LSRFortessa X-20 flow cytometer (BD Bioscience, San Jose, CA). Apoptosis was calculated by using the sum of annexin V-positive and PI/annexin V-double-positive cells.
Western Blot Analysis
Cell lysates were prepared using radioimmunoprecipitation assay buffer (Nacalai Tesque, Kyoto, Japan) supplemented with a phosphatase inhibitor (Nacalai Tesque). Western blot analysis was performed according 
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Trametinib, 4-MU Target ERK and CD44 in MPMto a standard protocol. Peroxidase-based chemiluminescence was developed by the addition of enhanced chemiluminescence (GE Healthcare Life Sciences, Pittsburgh, PA), and the protein bands were detected with an ImageQuant LAS 4010 device (GE Healthcare Life Sciences) and quantified using ImageQuant TL software (GE Healthcare Life Sciences).
RNA Interference
ERK1 and ERK2 knockdown was performed by transfection using MAPK1 Silencer Select Validated Small Intefering RNA (siRNA (Life Technologies, Carlsbad, CA), MAPK3 Silencer Select Validated siRNA (Life Technologies), and Lipofectamine RNAiMax (Invitrogen, Eugene, OR) according to the manufacturer's instructions. Tumors were measured twice a week with a Vernier caliper, and approximate tumor volumes were calculated using the following equation: tumor volume (in mm 3 ) ¼ (length Â width 2 ) Â 0.5. Statistical analysis was conducted using Tukey's test with GraphPad Prism 6 software for Windows, version 6.03 (GraphPad Software, La Jolla, CA). Expression of phosphorylated ERK, programmed cell death 1 (PD-1), and programmed cell death 1 ligand 1 (PD-L1) in xenografted NCI-H226 tumor tissue was examined by Western blot analysis and immunohistochemistry with phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) and PD-L1 (Cell Signaling Technology) and human PD-1 antibodies (AF1086) (R&D Systems) according to the manufacturer's protocol. Xenografted NCI-H226 tumor tissue was harvested at 4 hours, 1 day, and 4 days after the final dosing with trametinib and/or 4-MU. Excised tumor tissue was lysed using radioimmunoprecipitation assay buffer supplemented with phosphatase inhibitor for Western blot analysis. Tumor tissue was fixed in 10% formalin for 24 hours and then transferred to ethanol before paraffin embedding in preparation for immunohistochemistry. Phosphorylated ERK-positive cells, PD-1-positive cells, and PD-L1-positive cells were counted at high magnification (Â400) in 10 random fields per tumor and the counts were expressed as a percentage of the total number of cells observed for each tumor. Statistical analysis was conducted by using one-way analysis of variance with GraphPad Prism 6 software for Windows, version 6.03 (GraphPad Software).
Tumor Xenograft Study
Results
Trametinib and 4-MU Decrease Cell Viability in MPM Cells
Treatment with trametinib resulted in a concentrationdependent decrease in the number of live cells, with concentration that inhibits 50 percent (IC 50 ) values (Fig. 1B) . Next, we analyzed trametinib or 4-MU-treated NCI-H226 or MSTO-211H cells for the induction of apoptosis by annexin V/PI analysis. Treatment with trametinib resulted in a concentration-dependent increase in the number of apoptosis cells. Treatment of NCI-H226 cells with 4-MU resulted in a concentration-dependent increase in the number of apoptotic cells. 4-MU treatment did not induce apoptosis in MSTO-211H cells (Fig. 1C) . Trametinib or 4-MU leads to reduced cell viability through the induction of apoptosis in MPM cells.
Trametinib Blocks ERK Phosphorylation and Inhibits CD44 Expression
To examine the effect of trametinib alone on intracellular signaling, we performed Western blot analyses on MPM cells. NCI-H226 and MSTO-211H cells were treated with various concentrations of trametinib for 72 hours, and the phosphorylation status of the Raf-MEK-ERK and phosphoinositide 3-kinase (PI3K)-AKT pathways was analyzed. In addition, NCI-H226 and MSTO-211H cells were treated with 20 mM and 1 mM trametinib, respectively, and examined in time course analyses. As shown in Figure 2A and B, trametinib inhibited the phosphorylation of ERK and decreased the protein level of CD44 in a concentration-dependent manner. The time course analyses showed that trametinib reduced the phosphorylation of ERK to undetectable levels within 1 hour of exposure to the drug and that the protein level of CD44 was decreased (48-72 h) after suppression of ERK phosphorylation by trametinib ( Fig. 2C and D) . In addition, we analyzed whether CD44 expression is decreased by ERK1/2 knockdown to examine the association between the expression of ERK and that of CD44. As shown in Figure 2E , consistent with the knockdown of both ERK1 and ERK2, CD44 expression was decreased. These results suggest that CD44 is associated with ERK expression in MPM cells.
Effect of 4-MU on Intracellular Signaling Pathways
To examine the effect of 4-MU alone on intracellular signaling, we performed Western blot analysis on MPM cells. NCI-H226 cells were treated with 4-MU (10-100 mM) for 72 hours, and the phosphorylation status of the Raf-MEK-ERK and PI3K-AKT pathways was analyzed. In several tumor cell types, the interaction between HA and HA receptors activates various downstream signaling pathways, including the MAPK and PI3K-AKT pathways.
14 However, in the present study, 4-MU treatment only slightly inhibited the phosphorylation of ERK at high concentrations, and it was associated with increased ERK phosphorylation at low concentrations (up to 100 nM) in NCI-H226 cells. In addition, the level of CD44 protein expression did not significantly decrease in response to 4-MU treatment in NCI-H226 cells, unlike in previous reports (Fig. 2F ).
CD44 Expression Is Associated with ERK-Dependent Fra-1 Expression
We analyzed Fra-1 expression to examine the association between the expression of phosphorylated ERK and that of CD44. Consistent with the inhibition of phosphorylated ERK and CD44, Fra-1 expression was also inhibited by trametinib, 4-MU, and the combination of the two drugs in a concentration-dependent manner (Fig. 3) . These results suggest that CD44 is associated with ERK-dependent Fra-1 expression in MPM cells. (Fig. 4A) .
Trametinib and 4-MU Have Antitumor Effects in a Mouse Xenograft Model
We then examined the effects of trametinib, 4-MU, and their combination on ERK activation in vivo.
The Western blot analysis showed that trametinib treatment, at doses of both 1 and 3 mg/kg, potently inhibited ERK phosphorylation. In addition, treatment with the combination of trametinib and 4-MU resulted in inhibition of ERK phosphorylation similar to that after treatment with trametinib alone (Fig. 4B) .
The immunohistochemical analysis showed that both trametinib and 4-MU alone significantly inhibi- (Fig. 5) . In addition, combination treatment resulted in a significantly greater inhibition of Ki-67 expression, although neither monotherapy inhibited Ki-67 expression significantly (combination versus control, p < 0.0001) ( Supplementary  Fig. 1 ).
Trametinib and 4-MU Affect the Expression of the Immune Checkpoint Proteins PD-1 and PD-L1 in a Mouse Xenograft Model
To determine whether trametinib and 4-MU exhibit immunological effects in MPM cells, we assessed the expression of PD-1 and PD-L1 in the NCI-H226 mouse xenograft model. The Western blot analysis showed that trametinib treatment alone, at doses of both 1 and 3 mg/kg, reduced the expression of PD-1 and PD-L1, although there was no significant change in the expression of PD-1 and PD-L1 with 4-MU treatment alone or with the combination of trametinib and 4-MU ( Fig. 4B3 and B4) . The immunohistochemical analysis showed that trametinib treatment alone, at doses of both 1 and 3 mg/kg/d, significantly reduced PD-L1 expression (p < 0.0001 and p < 0.001, respectively), and 4-MU treatment alone significantly increased the expression of PD-1 and PD-L1 (p < 0.0001 and p < 0.0001, respectively), although there was no significant change in PD-1 expression with trametinib treatment alone. Furthermore, the combination of trametinib and 4-MU resulted in higher expression of PD-1 and PD-L1 than did the 4-MU treatment alone (p < 0.0001 and p < 0.0001, respectively) (Fig. 6) . 
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Discussion
Although MPM is not associated with mutations of EGFR or its downstream signaling pathway, 30 the multiple receptor tyrosine kinases EGFR, MET protooncogene, receptor tyrosine kinase (c-met) gene and AXL receptor tyrosine kinase are up-regulated and activated in MPM, [31] [32] [33] resulting in downstream activation of the MAPK and PI3K/AKT/mammalian target of rapamycin pathways. 34 Therefore, we focused our attention on suppression of the MAPK pathway by use of the MEK inhibitor trametinib. HA activates many downstream signal transduction pathways by binding to cell surface receptors such as CD44, consequently promoting cell proliferation, survival, motility, invasiveness, and chemoresistance. 11, 12 Suppression of HA production has been shown to inhibit a variety of HA-mediated tumor activities in various malignancies. [20] [21] [22] [23] [24] [25] [26] [27] As HA overexpression has been demonstrated in many cases of MPM, we hypothesized that similar antitumor effects may be achieved by using the HA synthesis inhibitor 4-MU. As previously mentioned, both trametinib and 4-MU are currently in clinical use, which gives them an advantage as therapeutic agents. Our in vitro and in vivo experiments demonstrated that both trametinib and 4-MU had antitumor effects in MPM. Furthermore, we demonstrated that treatment with a combination of the two drugs had a more potent antitumor effect.
The antitumor effect of trametinib on MPM was demonstrated both in vitro and in vivo. Trametinib decreased cell viability in all four MPM cell lines in a concentration-dependent manner. In Western blot analysis, trametinib strongly inhibited ERK phosphorylation in MSTO-211H cells and NCI-H226 cells. In the mouse xenograft model, trametinib significantly suppressed tumor growth and strongly inhibited the phosphorylation of ERK. However, this inhibition was lost a day after cessation of treatment (data not shown). Hence, although trametinib has a long circulating half-life, 10 daily dosing is required to achieve sustained inhibition of ERK phosphorylation. These results also provide evidence of a relationship between antitumor activity and the expression of phosphorylated ERK in MPM.
In addition, we demonstrated that CD44 expression was inhibited by trametinib and the knockdown of both ERK1 and ERK2. The transcription factor AP1 is a major target of asbestos-induced signal pathways. Ramos-Nino et al. reported that in rat pleural mesothelioma cells, expression of Fra-1 (the major component of AP1) depends on the activation of ERK 35 and that induction of cd44 is linked to the expression of fra-1. 36 In addition, they reported that Fra-1 was regulated by the ERK, Srk, and PI3K pathways in human malignant mesothelioma cells. 37 The AP1 transcription factor is an important component of many signal transduction pathways and is composed of dimeric complexes of Jun (c-Jun, JunD, and JunB) and Fos (c-fos, FosB, Fra-1, and Fra-2) family proteins. Since the discovery of AP1 more than 20 years ago, accumulating evidence has implicated it in the regulation of cellular processes such as proliferation, differentiation, growth, apoptosis, cell migration, transformation, and wound healing. 38 Previous reports have indicated that ERK signaling under conditions of Ras transformation not only induces expression of Fra-1 and c-Jun but also augments their transcriptional activity through phosphorylation. 39, 40 In addition, ERKdependent Fra-1 expression is significantly increased in both asbestos-exposed rat pleural mesothelial cells and mesothelioma cell lines and is required for mesothelial cell transformation. 35 Some reports have indicated that fra-1 regulates the expression of c-met and cd44 mRNA. 36 In oral cavity squamous cell carcinomas, RAS/ MEK/ERK and AP1 cascades trigger the transcription and expression of CD44, which contributes to increased tumor aggressiveness. 41 On the basis of these reports, we suggest that trametinib inhibited the expression of CD44 through inhibition of ERK phosphorylation and Fra-1 expression in the present study. These findings imply that the MAPK pathway regulates CD44 expression in MPM. CD44 is a major receptor for HA, and HA-CD44 binding activates downstream signaling pathways such as the MAPK and PI3K/AKT pathways, resulting in the promotion of tumor cell proliferation, survival, motility, invasiveness, metastases, and chemoresistance. 11, [42] [43] [44] [45] In addition, HA-CD44 binding causes direct or indirect interaction with signaling receptors such as EGFR, erb-b2 receptor tyrosine kinase 2, transforming growth factor-b, and c-met and activates these receptors; this activation is inhibited by 
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Trametinib, 4-MU Target ERK and CD44 in MPMsuppression of CD44. 11, 12, 45, 46 The findings of the present study suggest that the potent antitumor effects of trametinib on MPM in vitro and in vivo were induced not only by inhibition of the MAPK pathway but also by suppression of CD44.
4-MU also exhibited antitumor activity in MPM in vitro and in vivo. These results are in agreement with previous studies that demonstrated antitumor effects of 4-MU (such as antiproliferation; induction of apoptosis; inhibition of cell motility and invasiveness, MAPK and PI3K/AKT pathways, and HAS [HAS2 and HAS3] and NFkappa B expression; and downregulation of HA receptors [CD44 and hyaluronan mediated motility receptor]) in vitro in addition to inhibition of tumor growth or metastasis in vivo for several types of malignancies. [19] [20] [21] [22] [23] [24] [25] [26] [27] As 4-MU-induced antitumor activity in vitro is abrogated by the addition of HA, it is suggested that 4-MU acts by inhibiting HA synthesis. It has also been reported that 4-MU inhibits proliferation, motility, and HA synthesis of fibroblasts in tumor stroma. 23 In MPM, HA is produced by mesothelioma cells and surrounding normal cells such as mesothelial cells and fibroblasts. 14, 15 In the present study, although 4-MU did not inhibit CD44 expression, unlike in previous studies, it decreased cell viability and ERK phosphorylation in vitro and inhibited tumor growth and ERK phosphorylation in a mouse xenograft model. These findings suggest that 4-MUinduced antitumor effects on MPM were caused by inhibition of the MAPK pathway.
Our findings also demonstrated the enhanced antitumor effect of using a combination of trametinib and 4-MU on MPM. In vitro analysis showed that the combination treatment blocked ERK phosphorylation and inhibited CD44 expression, and in the mouse xenograft model, the combination treatment significantly suppressed tumor growth compared with either monotherapy.
In addition, we demonstrated that the expression of PD-1 and PD-L1 was reduced by trametinib treatment alone and increased by 4-MU treatment alone in MPM in vivo. The combination treatment exhibited greater induction of PD-1 and PD-L1 expression than 4-MU treatment alone.
Similar to our results, a recent report demonstrated that MAPK inhibitors including trametinib affect PD-L1 expression and that combination of trametinib with an immune checkpoint inhibitor targeting PD-1, PD-L1, and cytotoxic T-lymphocyte-associated antigen 4 was more efficacious than any single agent. 47 Another recent report suggested that HA may form a physical barrier inhibiting the access of both monoclonal antibody therapy and immune cells and that anticancer monoclonal antibodies under HA depletion may be an effective adjunctive therapy for HA-rich tumors. 48 On the basis of these reports, our results suggest that both trametinib and 4-MU affected the immune function of MPM cells and a combination of these agents with an immune checkpoint inhibitor may have a further increased effect in MPM.
In conclusion, we have demonstrated the antitumor effects of trametinib, a MEK inhibitor, and 4-MU, an HA synthesis inhibitor, on MPM cell lines. Furthermore, we have demonstrated that treatment with a combination of the two drugs yielded more potent antitumor effects on MPM cells than monotherapy with either drug. Both trametinib and 4-MU are currently used in clinical applications and represent promising novel therapeutic strategies for MPM.
